If you are an individual or entity who paid any amount of money for retail purchases of Hetero Valsartan, Aurobindo Irbesartan, or Vivimed Losartan medications between January 1, 2016 and the present, you could receive a payment from class action settlements
CAMDEN, N.J., April 2, 2026 /PRNewswire/ -- The following notice is being issued by the Court approved Settlement Administrator and has been authorized by the U.S. District Court for the District of New Jersey, in In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation, Case No. 1:19-md-02875-RBK-SAK.
Settlements have been reached in economic loss class action lawsuits against Hetero Drugs, Ltd., Hetero Labs Ltd., Hetero USA, Inc., and Camber Pharmaceuticals, Inc. (collectively, "Hetero"); Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., and Aurolife Pharma LLC (collectively, "Aurobindo"); and Vivimed Life Sciences Pvt Ltd and Strides Pharma Science Limited (collectively, "Vivimed"). These Settlements are part of a larger lawsuit, In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation, Case No. 1:19-md-02875 (MDL No. 2875), currently pending in the United States District Court for the District of New Jersey (the "Court").
The lawsuit alleges that certain batches of Hetero Valsartan, Aurobindo Irbesartan, and Vivimed Losartan finished drug formulations were manufactured using active pharmaceutical ingredients ("API") contaminated with probable human carcinogens, including NDMA, NDEA, and NMBA, resulting in economic losses to consumers and third-party payors. Each Defendant denies any wrongdoing, denies that the levels of nitrosamine impurities were harmful or carcinogenic, and has asserted various legal and factual defenses. The Court has not decided whether any defendant did anything wrong or whether the Plaintiffs' claims have merit.
These Settlements resolve only the economic loss claims against the settling Defendants for the drugs identified below. Please read this notice carefully. Your legal rights are affected whether you act or don't act.
Who is Included?
The Settlement Class includes all individuals and third-party payors in the United States, its territories, and possessions who paid any amount of money for retail purchases of:
- Valsartan finished drug formulations containing Hetero Process III Valsartan API, sold between May 1, 2018 and July 31, 2018;
- Losartan finished drug formulations sold under the following Vivimed National Drug Codes ("NDCs"): 23155-644-09, 23155-644-10, 23155-645-03, 23155-645-09, 23155-645-10, 23155-646-03, 23155-646-09, and 23155-646-10;
- Irbesartan finished drug formulations manufactured using Aurobindo's IC Route of Synthesis ("IC ROS Irbesartan"), purchased from January 1, 2016 to the present.
Detailed information regarding the Class is viewable at www.SartanMedicationSettlement.com.
What Does the Settlement Provide?
Based on an evaluation of the quantity and pricing of the eligible pills sold, Hetero will pay $11,365,489.80; Aurobindo will pay $2,000,000; and Vivimed will pay $1,899,000.
Full details, including how funds will be distributed between consumers and third-party payors, may be found at www.SartanMedicationSettlement.com.
What Are My Rights And Options?
Submit a Claim: To receive a Settlement payment, you must submit a Claim Form. You can submit your Claim online at the Settlement Website or download a paper Claim Form to mail in. Certain Claims may require supporting documentation. Class Members are limited to one claim per Class Member. Related companies such as corporate subsidiaries or affiliates may file claims either separately or combined. However, no more than one claim may be submitted for the same payments. Your Claim Form must be submitted online or postmarked by June 2, 2026.
Do Nothing: If you do nothing, you will remain a part of the Class and Settlement. You will receive no payment under the Settlement and you will give up your rights to sue the settling Defendants about the issues in this case.
Opt-Out: Excluding yourself is the only way to keep your right to sue the settling Defendants over the claims in this case. You won't be bound by the Settlement, but you also won't receive any payment from it, if one is awarded. To opt-out, you must submit an exclusion request, along with proof of class member status or declaration under penalty of perjury, to the Settlement Administrator postmarked or emailed and received no later than June 2, 2026.
Object: If you do not like any part of the Settlement, you can object by writing to the Court. You cannot submit both an exclusion request and objection. To Object, you must remain a Class Member. If the Court grants Final Approval over your objection, you will give up your rights to sue the settling Defendants about the issues in this case. If you also wish to receive payment from the Settlement, you must submit a Claim Form. Your objection must be postmarked no later than June 2, 2026.
Complete details about how to submit a Claim, opt-out, and object are available at www.SartanMedicationSettlement.com.
Do I have a lawyer in this case? Yes, if you do not exclude yourself by opting out. The Court has appointed Ruben Honik, Esq., Honik Law, Conlee S. Whiteley, Esq., Kanner & Whiteley, LLP and John R. Davis, Esq., Slack Davis Sanger LLP to represent the Consumer Economic Loss Class and Gregory P. Hansel, Esq., Preti Flaherty Beliveau & Pachios, Chartered, LLP and Jorge A. Mestre, Esq., Rivero Mestre LLP to represent the TPP Class.
Where can I get more information? This is only a summary. For more information regarding the detailed allegations for the three settling Defendants, visit www.SartanMedicationSettlement.com or call 1-866-875-9644.
Please do not write or call the Court or the Clerk's Office for information.
SOURCE Sartan Settlement Administrator
Share this article